For women with breast cancer, incorporating yoga into radiotherapy is associated with a lasting improvement in quality of life.
A panel of 55 genes, almost all of which are impacted by the loss of a particular protein, appears to predict if breast cancer will become invasive, leading to poorer survival, according to new research.
A new study shows that targeting a particular nuclear protein may provide an effective approach for treating triple-negative breast cancer.
Possible genetic origins of breast cancer that spreads to the brain have been uncovered, according to a first-of-its-kind study.
Small noncoding RNAs can be used to predict if a person has breast cancer, concluded researchers who contributed to The Cancer Genome Atlas (TCGA) project.
A protein that fuels an inflammatory pathway does not turn off in breast cancer, resulting in an increase in cancer stem cells, according to new research.
Digital mammography screening with the new photon-counting technique offers high diagnostic performance, according to a new study.
The researchers found that use of breast reconstruction in women undergoing mastectomy for breast cancer increased significantly, from 46 percent in 1998 to 63 percent in 2007.
Androgen and vitamin D receptors can be targeted in breast cancer, according to new research.
Improvements in fatigue, IL-6, TNF-a, and IL-1B seen in a clinical trial that measured the effects of yoga practice in women survivors of breast cancer.
Breast cancer was diagnosed at earlier stages in women age 40 to 49 years who underwent routine screening mammography, and their tumors were less likely to require chemotherapy.
Positive margins linked to two-fold increased risk of ipsilateral breast tumor recurrence, according to consensus guidelines.
Observational study supports removal of contralateral breast in women with hereditary breast cancer.
Long-term outcomes of breast cancer patients receiving adjuvant accelerated partial breast irradiation after breast-conserving surgery show excellent tumor control with minimal late toxicity.
Standard external beam radiation therapy provided a higher breast preservation rate than brachytherapy in women 66 years and older with invasive breast cancer, according to new research.
Contrary to existing understanding, long-term follow-up of patients with two types of breast tissue abnormalities suggests that both types of abnormalities have the same potential to progress to breast cancer.
When comparing treatments designed to enable long-term breast preservation for older women with invasive breast cancer, researchers found that those treated with brachytherapy were at higher risk for a later mastectomy.
Researchers have found amplification of HER2—a known driver of some breast cancers—in a type of bladder cancer called micropapillary urothelial carcinoma (MPUC).
Younger women who smoke appear to be at increased risk for developing ER-positive breast cancer, according to research, but no association found for risk of triple-negative breast cancer.
Years can pass between the time a breast cancer patient goes into remission and a related brain tumor develops. During that time, the breast cancer cells somehow escape detection.
Researchers found a significantly reduced mortality risk for breast cancer survivors who run.
Critical complex mechanisms involved in the metastasis of deadly triple-negative breast cancers (TNBC) have been identified.
Research has not only shown that HER2-positive breast cancer can be classified into four different subtypes, but has also unmasked a subtype showing both a greater response to and increased benefit from chemotherapy and anti-HER2 therapy.
Girls treated for Hodgkin's lymphoma during adolescence acquire a considerable risk of developing breast cancer.
Twelve-week intervention linked to improved fatigue, vitality, lower levels of proinflammatory cytokines in participants.
Breast cancer stem cells exist in two different states and each state plays a role in how cancer spreads, according to an international collaboration of researchers.
Semiautomated computer-derived measurements are consistent with radiologist assessments, according to a study.
A patient on adjuvant endocrine therapy for breast cancer is complaining of hair loss. Could the alopecia be due to her endocrine therapy?
Preventive surgery improves survival for women who are at greater risk of developing ovarian cancer, and it may be helpful for women at risk of developing breast cancer due to genetics.
A protein has been identified that may be a key culprit when breast cancer metastasizes to the brain.
Women with breast cancer who undergo surgery rate persistent postmastectomy pain as the most troubling symptom.
Measuring the amount of certain protein fragments and microRNAs in a woman's blood and breast tissue might enable the early diagnosis of breast cancer or prediction of its metastasis.
A cellular mechanism has been discovered that drives breast cancer metastasis, and researchers have also discovered a therapy that blocks that mechanism.
Aerobic glycolysis, which is glucose metabolism in the presence of oxygen, has been shown to be a cancerous event, rather than a consequence of the cancerous activity of malignant cells.
Radiotherapy after breast-conserving surgery has been shown to reduce the risk of breast cancer recurrence. But younger women are less likely to receive radiotherapy after breast-conserving surgery, according to a new study.
An investigational new PARP inhibitor, BMN 673, is showing early responses in patients with advanced, BRCA-related breast and ovarian cancers.
In a study that included more than 800 women who had undergone surgery for breast cancer, the majority reported some level of pain 12 months after surgery.
Women with HER2-positive breast cancer who had the highest levels of immune cells in their tumors gained the most benefit from presurgery treatment with chemotherapy and trastuzumab. These results were presented at the 2013 San Antonio Breast Cancer Symposium.
After a response to initial chemotherapy, treatment with radiotherapy and surgical removal of the breast tumor and nearby lymph nodes do not provide any additional benefit to patients with metastatic breast cancer.
Combining the chemotherapy drugs docetaxel and carboplatin with the HER2-targeted therapy trastuzumab was identified to be an ideal postsurgery treatment option for patients with HER2-positive breast cancer.
A nearly 20-year observational study involving more than 44,700 black women nationwide found that regular vigorous exercise offers significant protection against development of an aggressive subtype of breast cancer.
Re-examination of data from four large studies of the benefits and harms of mammography screening shows that the benefits are more consistent across these studies than previously understood.
Changes in the genetic composition of breast cancer tumors after brief exposure to either biologic therapy or chemotherapy can predict future clinical outcomes in patients, according to new research.
Omission of radiotherapy is a reasonable option for women 65 years or older who receive hormone therapy after breast-conserving surgery for hormone receptor-positive, axillary node-negative breast cancer.
Human breast tumors transplanted into mice are excellent models of metastatic cancer and are providing insights into how to attack breast cancers that no longer respond to the drugs used to treat them, according to research presented at the 2013 San Antonio Breast Cancer Symposium.
More than one-third of younger, early-stage breast cancer patients undergo unnecessary imaging procedures at the time of staging and diagnosis, according to research presented at the 2013 San Antonio Breast Cancer Symposium.
Among 1,000 U.S. women screened annually for 10 years, 0.3 to 3.2 will avoid breast cancer death due to mammography.
Breast cancer survivors taking AIs, such as anastrozole, letrozole, and exemestane, experienced a reduction in joint pain if they exercised while on treatment. These results were presented at the 2013 San Antonio Breast Cancer Symposium.
Most women with unilateral non-metastasized breast cancer treated with breast conserving surgery or mastectomy with axillary surgery experience postoperative pain at 12 months, according to research.
Women with breast cancer characterized by high levels of the protein HER2 and hormone receptors gained much less benefit from presurgery treatment with chemotherapy and HER2-targeted therapies if their cancer had one or more mutations in the PIK3CA gene. These results were presented at the 2013 San Antonio Breast Cancer Symposium.
Adding dasatinib to the standard antihormone therapy, letrozole, doubled the time before disease progressed for women with hormone receptor-positive, HER2-negative metastatic breast cancer. These results of a phase 2 clinical trial were presented at the 2013 San Antonio Breast Cancer Symposium.
The first investigator results from an unprecedented nationwide effort to test promising new breast cancer drugs before the tumor is removed were presented during the 2013 San Antonio Breast Cancer Symposium.
Breast cancer incidence among postmenopausal women at high risk for developing the disease was significantly reduced with the antihormone therapy anastrozole, according to the initial results of a double-blind, randomized, placebo-controlled trial presented at the 2013 San Antonio Breast Cancer Symposium.
Many relatives of patients who undergo testing for genetic links to breast and ovarian cancers misinterpret the results, and less than half of those who could benefit from genetic testing say they plan to undergo testing themselves, according to a recent study presented at the 2013 San Antonio Breast Cancer Symposium.
Adding the antibody therapy ramucirumab to docetaxel therapy did not delay disease progression for patients with HER2-negative, advanced breast cancer. These results, from a placebo-controlled, randomized, phase 3 clinical trial, were presented at the 2013 San Antonio Breast Cancer Symposium.
No significant difference in outcomes seen for patients treated with real or sham acupuncture; both groups saw improvement.
I-SPY 2 has yielded positive results with the first drug to complete testing during the trial. Adding carboplatin and veliparib to standard presurgery chemotherapy improved outcomes for women with triple-negative breast cancer, according to results presented at the 2013 San Antonio Breast Cancer Symposium.
Treatment with zoledronate, a bisphosphonate, did not improve outcomes for women with chemoresistant breast cancer, according to initial results of a phase 3 clinical trial presented at the 2013 San Antonio Breast Cancer Symposium.
For women with metastatic breast cancer who had elevated amounts of CTCs in their blood after a first line of chemotherapy, switching immediately to a different chemotherapy did not improve overall survival or time to progression. These phase 3 clinical trial results were presented at the 2013 San Antonio Breast Cancer Symposium.
The metabolic profile of cancer cells can be used to develop therapies and identify biomarkers associated with cancer outcome. New research has discovered an association between the oncometabolite 2-HG levels, DNA methylation patterns, and breast cancer prognosis.
Increased levels of the protein HSET in African American women with breast cancer were associated with worse outcomes, according to results presented at the Sixth AACR Conference on the Science of Cancer Health Disparities in Racial/Ethnic Minorities and the Medically Underserved, in Atlanta.
Older breast cancer survivors should follow an ongoing exercise program of resistance and impact training. Newly published research found that the bone benefit from 1 year of such training could be maintained, even with less exercise, up to a year later, which could help prevent bone fractures in the long run.
Imaging with a molecular imaging tracer can help distinguish radiation-induced lesions from new tumor growth in patients who have been treated with radiation for brain metastases, according to new research.
Compared with traditional mammography, 3D mammography—known as digital breast tomosynthesis—found 22% more breast cancers and led to fewer callbacks in a large screening study, as researchers reported at the annual meeting of the Radiological Society of North America.
Automated breast density measurement is predictive of breast cancer risk in younger women, and that risk may be related to the rate at which breast density changes in some women as they age, according to research.
A new study finds that survivors of hematopoietic stem cell transplant, an aggressive treatment for blood cancers, benefited from a two-part peer support process. The authors called this peer support process "expressive helping."
Two studies show increase in pathologic complete response with pre-op chemotherapy combinations.
Anastrozole reduces breast cancer risk by about half with few side effects, according to a study presented at the annual San Antonio Breast Cancer Symposium.
Radiotherapy has no benefit for some older women after surgery, and hormone treatment after surgery may provide a radiation alternative.
A by-product of cholesterol functions like the hormone estrogen to fuel the growth and spread of the most common types of breast cancers, according to researchers.
Apparent disparities between different reviews on the benefit of mammography screening on breast cancer mortality are mainly due to different denominators.
In addition to infrequent exercise, a larger breast cup size was also linked with increased risk of breast cancer mortality in female runners and walkers.
For human epidermal growth factor receptor 2 (HER2)-positive tumors, the combination of lapatinib and trastuzumab is better than either therapy alone, according to a study.
Researchers have discovered why some of the most aggressive and fatal breast cancer cells are resistant to chemotherapy, and they are developing ways to overcome this resistance.
Lymphedema can be accurately assessed through the use of Bioelectrical Impedance Analysis (BIA) ratios, according to a new study.
A new blood test for peptides cleaved by carboxypeptidase N may soon be available to help detect early stages of breast cancer.
McMaster University researchers found no difference in patients with breast cancer who used simple compression bandages to treat lymphedema compared with those who underwent daily lymphatic massage.
As cholesterol is metabolized, a potent stimulant of breast cancer is created—one that fuels estrogen receptor (ER)-positive breast cancers, according to new research.
Software that recognizes patterns in data is commonly used by scientists and economists. Now, researchers in the United States have applied similar algorithms to help them more accurately diagnose breast cancer.
A screening mammography interval of less than 1.5 years is associated with a significantly reduced rate of lymph node positivity.
Use of digital breast tomosynthesis (DBT) demonstrated reduced callback rates and improved cancer detection when compared with mammography.
Mammographic density is associated with breast cancer among women younger than 50 years, according to a study.
A type of mutation that develops after breast cancer patients take antiestrogen therapies has been identified. These mutations help to explain why patients often become resistant to these types of therapies.
Women from BRCA2 families without mutation still have higher breast cancer risk.
More than 500,000 women in the United States have a breast biopsy each year. Percutaneous biopsies are associated with fewer complications than the surgical approach, but short-term side effects such as pain and emotional distress are still significant.
Giving trastuzumab and anthracyclines concurrently is not necessary to achieve a high rate of complete pathologic remission in HER2-positive breast cancer. The results of a recent phase III clinical trial show that administering the treatments sequentially is equally effective.
Mutations in the genes that defend the body against cancer-related viruses and other infections may play a larger role in breast cancer than previously thought.
A large national study has found that the rate of women undergoing magnetic resonance imaging (MRI) of the breast nearly tripled from 2005 to 2009: from four to 11 examinations per 1,000 women.
Testing Morbidities Index scores are down by about three points for each decade decrease in the patient's age.
Two studies show increases in MRI use; few meet criteria of American Cancer Society for screening.
Breast conservation less frequently performed for males with breast cancer, according to research.
Although a breast cancer diagnosis is usually an extremely stressful experience for most women, a new study has found that there also can be unexpected benefits.
Persistent postmastectomy pain is rated by survivors as the most troubling symptom by women with breast cancer who undergo surgery.
Among patients with early stages of breast cancer, the risk of heart disease is higher for those whose hearts were more directly irradiated with radiation treatments on the left side in a facing-up position.
Two studies show promising results in invasive ductal carcinoma and early breast cancer.
Patient assistance programs can help breast cancer patients meet a variety of needs. When these needs are unmet, they can interfere with getting recommended adjuvant therapies such as radiation, chemotherapy, and hormonal treatments.
Breast cancer cell growth, motility, and aggression is promoted by excess glucose, as experienced by patients with diabetes and metabolic syndrome, reports a new study.
Can the drug paroxetine mesylate (Brisdelle, Paxil) be given to patients taking a chemoprevention drug such as raloxifene (Evista) or any of the aromatase inhibitors?
An investigational new PARP inhibitor, BMN 673, is showing early responses in patients with heavily pretreated, advanced, BRCA-related cancers of the breast and ovary.
A small-molecule inhibitor of CDK 4/6 being developed showed promising results in drug-resistant melanoma and drug-resistant breast cancer when tested in combination with other targeted therapies.
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|